PIAS1 sirna

PIAS1 siRNA (Human)

Cat. Num. AAA8222124

• Gene Names: PIAS1; GBP; ZMIZ3; DDXBP1; GU/RH-II
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: PIAS1; PIAS1 siRNA (Human); DDXBP1; E3 SUMO-protein ligase PIAS1; DEAD/H box-binding protein 1; Gu-binding protein; GBP; Protein inhibitor of activated STAT protein 1; RNA helicase II-binding protein; PIAS1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: PIAS1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 651

• Applicable Applications for PIAS1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human PIAS1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for PIAS1 sirna

siRNA to inhibit PIAS1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 7706637
• NCBI GeneID: 8554
• NCBI Accession #: NP_057250.1
• NCBI GenBank Nucleotide #: NM_016166.1
• UniProt Accession #: O75925; Q147X4; Q99751; Q9UN02; B2RB67; B3KSY9; C5J4B4
• Molecular Weight: 36,204 Da
• NCBI Official Full Name: E3 SUMO-protein ligase PIAS1
• NCBI Official Synonym Full Names: protein inhibitor of activated STAT, 1
• NCBI Official Symbol: PIAS1
• NCBI Official Synonym Symbols: GBP; ZMIZ3; DDXBP1; GU/RH-II
• NCBI Protein Information: E3 SUMO-protein ligase PIAS1
• UniProt Protein Name: E3 SUMO-protein ligase PIAS1
• Protein Family: E3 SUMO-protein ligase
• UniProt Gene Name: PIAS1
• UniProt Synonym Gene Names: DDXBP1; GBP
• UniProt Entry Name: PIAS1_HUMAN

NCBI Description

This gene encodes a member of the mammalian PIAS [protein inhibitor of activated STAT-1 (signal transducer and activator of transcription-1)] family. This member contains a putative zinc-binding motif and a highly acidic region. It inhibits STAT1-mediated gene activation and the DNA binding activity, binds to Gu protein/RNA helicase II/DEAD box polypeptide 21, and interacts with androgen receptor (AR). It functions in testis as a nuclear receptor transcriptional coregulator and may have a role in AR initiation and maintenance of spermatogenesis. [provided by RefSeq, Jul 2008]

Uniprot Description

PIAS1: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. In vitro, binds A/T-rich DNA. The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context. Together with PRMT1, may repress STAT1 transcriptional activity, in the late phase of interferon gamma (IFN-gamma) signaling. Interacts with NCOA2 and AR. Interacts with NR2C1; the interaction promotes its sumoylation. Interacts with DDX21, CSRP2, AXIN1, JUN, UBE2I, SUMO1, SATB2, PLAG1, TP53 and STAT1 (dimer), following IFNA1-stimulation. Interacts with SP3 (preferentially when SUMO-modified). Interacts with KLF8; the interaction results in SUMO ligation and repression of KLF8 transcriptional activity and of its cell cycle progression into G(1) phase. Interacts with STAT1. Interacts with CHUK/IKKA; this interaction induces PIAS1 phosphorylation. Interacts with PTK2/FAK1; the interaction promotes its sumoylation. Interacts with DDX5. Expressed in numerous tissues with highest level in testis. Belongs to the PIAS family.

Protein type: SUMO conjugating system; Nuclear receptor co-regulator; EC 6.3.2.-; Transcription, coactivator/corepressor

Chromosomal Location of Human Ortholog: 15q

Cellular Component: nucleoplasm; PML body; nuclear speck; nucleus

Molecular Function: protein domain specific binding; protein binding; enzyme binding; DNA binding; androgen receptor binding; zinc ion binding; ubiquitin protein ligase binding; transcription coactivator activity; transcription corepressor activity; ligase activity

Biological Process: transcription, DNA-dependent; positive regulation of smooth muscle cell differentiation; cytokine and chemokine mediated signaling pathway; positive regulation of transcription, DNA-dependent; negative regulation of transcription from RNA polymerase II promoter; JAK-STAT cascade; protein-DNA complex assembly; regulation of cell proliferation; positive regulation of protein sumoylation; protein sumoylation; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; androgen receptor signaling pathway; spermatogenesis